Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ques. For legal guys. If results were so obvious why DoD FDA insist on Yeats of study with thousands of patients? Weren't they the scientific expert who was most objective and in control? Why did Amrn spend $mm if everything was self evident?
Are the low sales projection analysts doing Amrn a favor? If you're in settlement talks you can present these professional estimates as sophisticated models when you negotiate. Just a thought
Does anyone know max pain point for next option expiration?
I'm not a JT apologist, but I think he has been told to stick to a tight script until the patent issue is resolved. Then we will see a sales revised sales projection. The recent price action is wall street way of saying we never expected V would get this far. We were caught off guard, but you loss ant retail investors will not gain until we are whole.
SEC fiddles while AMRN burns. That's the fact that upsets me the most.
Shorts are doing an excellent job of exiting their positions.
Some things I thought I heard. 2020 sales projection 650-700mm, but we had to revise out last projection upwards twice during the past year. Annual product capacity around 1billion and will be growing. Have to revisit some insurance carriers to expand coverage. Tv ads testing well, but mid year is target for release. No additional funding needed. Europe decision likely 4th qtr, 2020
Could this be buyout instead of FDA news
Washington post doing biotech manipulation article. Nwbo mentioned
When is next FDA review date?
Biochica. I agree with you. J.t. does not sell shares consistently, but always at critical times. The bod has not implemented any black out periods and it has hurt retail stock holders. Every time he sells there has been a short attack. Just coincidence , I guess.
Here. The grown ups are discussing life saving biopharma issues. Anyone who thinks this is a game, doesn't belong
Quesion. If secondary results are as terrific as indicated, should the company start an additional study naming 1 or more of the secondary outcomes as"primary". Why wait an sit on our hands for 9 more months to hear BUT you missed your primary Evaporate target.
Does anyone recall how much capacity Amrn locked up? Several months ago they noted an increase in anticipation of approval and to eliminate a potential obstacle.
If presenotations are as positive as expected it will provide cover for the FDA to provide a wider label. This combined with large short position should steadily move the stock price this week and each week into the Pdufa date.NB. shorts will be working hard to steal your shares. Watch your stop losses if you use them
GSremarls imply that they will exert maximum pressure on stock price
Any chance the Primary definition may be adjusted as the one panelist suggested. Giving V clearance for a portion of the Primary market?
AH. Ask 26. Small,shaky bids
Is there 1 more question to be voted on or is this the last vote
Based on total days discussions, were FDA reps positive on primary/diabetes?
Has FDA tipped their hand this early?
My post refers to j.t.
Their is either tone deaf or has the worst timing in the world. This is twice he sold mega sh a res into a critical market. He has purposely put shares out there helping the shorts to cover and dampening the short squeeze. The board needs to step up and stop such sales at critical times. This can be done when shares are awarded. This is a bush league move.
Can someone summarize AF's doctor comments
Louie would you post your findings re: closest hotel etc
I'm having a hard time imagining what a settlement would look like. Would it be less years of protection? Would it involve a royalty to Amrn for sales? Would it be for a less effective product strength??? Any ideas?
I believe ad com will focus on both issues. Because of DS industry input the MO issue must be put to bed. The second issue is label expansion. Management is pushing hard for BROAD expansion. FDA is busting chops. MO issue should be dismissed. Label issue will likely be a compromise IMHO
Hopefully Sam is on vacation having an umbrella drink
ICER report out on vacepa. (Amrn)
GS really went out on a limb. They expect a 1 dollar gain from today's price if ad com and pdufa are successful. Could be the smallest gain in history upon FDA positive action.
Raf news quiz. My guess - V cures ED
Go birds. E-A-G-L-E-S, eagles!
Be careful if you use Stop Loss feature with your accounts. Big players will scoop up these shares via manipulation.
Najarian has been very consistently positive on Amrn for more than a year
Najarian, 12k Nov. 17 calls bought
I have no idea what AF will say, but I can tell you he is untrustworthy and a convicted criminal who has shown he works for the highest bidder. He was formerly a mouthpiece for Cramers hedge fund contacts
Lei. Will Dr.Bhatt from Harvard be presenting AMRN case at Ad com?
The 64k question is, why would AHA put the company on the agenda knowing they failed to meet primary end point. Believe me they knew. Facts are embargoed until then. The company has something positive to say. Whether it moves the pps substantially is the other question.
Dew was on record as stating that V would not be as successful as bulls anticipate, particularly noting that it required taking 4 pills p e r day
Gg. Dndn may be the most manipulated stocks in history. SEC did nothing.